Craft

Advanced
  • Home
  •  / Verrica Pharmaceuticals
Verrica Pharmaceuticals

Verrica Pharmaceuticals

Stock Price

$1.7

2024-10-29

Market Capitalization

$71.7 M

2024-10-29

Revenue

$35.6 M

FY, 2025

Verrica Pharmaceuticals Summary

Company Summary

Overview
Verrica Pharmaceuticals develops and commercializes dermatological treatments. The Company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris.
Type
Public
Status
Active
Founded
2013
HQ
West Chester, PA, US | view all locations
Website
https://www.verrica.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Ted White

    Ted White, President & CEO

    • Mark Prygocki

      Mark Prygocki, Director

      • Gary Goldenberg

        Gary Goldenberg, Chief Medical Officer, Director

        • Sean Stalfort

          Sean Stalfort, Director

          LocationsView all

          1 location detected

          • West Chester, PA HQ

            United States

            10 N High St #200

          Verrica Pharmaceuticals Financials

          Summary Financials

          Revenue (Q1, 2026)
          $5.0M
          Net income (Q1, 2026)
          ($9.7M)
          Cash (Q1, 2026)
          $20.6M
          EBIT (Q1, 2026)
          ($9.7M)
          Enterprise value
          $52.1M

          Competitors and Similar Companies

          Compare competitors

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2026
          Share price data provided by IEX